Vitrolife announces changes to the executive management team after the acquisition of Igenomix

Published: Dec. 1, 2021 at 6:17 AM CST

GÖTEBORG, Sweden, Dec. 1, 2021 /PRNewswire/ -- As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.

The executive management team will from 1 January, 2022, consist of:

Thomas Axelsson, President and Chief Executive Officer

Group Functions:
Francisco Jiménez, SVP Strategy & Corporate Development
Karin Koritz Russberg, SVP HR & Sustainability
Carlos Simón, Chief Scientific Officer
Patrik Tolf, Chief Financial Officer

Business Areas:
Claus Bisgaard, SVP Vitrolife Technology
Ricardo Capella, SVP Igenomix
Maria Forss, SVP Vitrolife Consumables

Business Functions:
Rickard Ericsson, SVP Vitrolife Sales & Marketing
Francisco Rodriguez, SVP Igenomix Affiliates

Gothenburg, December 1, 2021
Thomas Axelsson, CEO


Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 1.00 pm CET on December 1, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision

The following files are available for download:

View original content:

SOURCE Vitrolife AB (publ)

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.